<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is debate in the literature over the relative importance of genetic instability and clonal expansion during progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is a uniquely suited model to investigate <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> prospectively because periodic endoscopic biopsy surveillance is recommended for early detection of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that expansion of clones with genetic instability would predict progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (<z:mp ids='MP_0004024'>aneuploidy</z:mp>, tetraploidy) within each <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> segment of a cohort of 267 research participants, who were followed prospectively with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as an outcome </plain></SENT>
<SENT sid="4" pm="."><plain>We defined the size of a lesion as the fraction of cells with the lesion multiplied by the length of the <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> segment </plain></SENT>
<SENT sid="5" pm="."><plain>A Cox proportional hazards regression indicates that the sizes of clones with p53 loss of heterozygosity (relative risk = 1.27(x) for an x cm clone; 95% confidence interval, 1.07-1.50) or ploidy abnormalities (relative risk = 1.31(x) for an x cm clone; 95% confidence interval, 1.07-1.60) predict progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> better than the mere presence of such clones (likelihood ratio test, P &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Controlling for length of the <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> segment had little effect </plain></SENT>
<SENT sid="7" pm="."><plain>The size of a clone with a p16 lesion is not a significant predictor of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> when we controlled for p53 loss of heterozygosity status </plain></SENT>
<SENT sid="8" pm="."><plain>The combination of clonal expansion and genetic instability is a better predictor of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> outcome than either alone </plain></SENT>
<SENT sid="9" pm="."><plain>This implies that interventions that limit expansion of genetically unstable clones may reduce risk of progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>